rs1800590
Positions:
Variant summary
Our verdict is Benign. Variant got -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBA1
The ENST00000524029.5(LPL):c.-153-128T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.056 in 516,462 control chromosomes in the GnomAD database, including 3,994 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.12 ( 3135 hom., cov: 32)
Exomes 𝑓: 0.029 ( 859 hom. )
Consequence
LPL
ENST00000524029.5 intron
ENST00000524029.5 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.707
Genes affected
LPL (HGNC:6677): (lipoprotein lipase) LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -18 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.41).
BP6
Variant 8-19939160-T-G is Benign according to our data. Variant chr8-19939160-T-G is described in ClinVar as [Benign]. Clinvar id is 362399.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-19939160-T-G is described in Lovd as [Likely_benign].
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.38 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LPL | ENST00000520959.5 | c.-140-9020T>G | intron_variant | 4 | ENSP00000428496 | |||||
LPL | ENST00000522701.5 | c.-218-63T>G | intron_variant | 4 | ENSP00000428557 | |||||
LPL | ENST00000524029.5 | c.-153-128T>G | intron_variant | 4 | ENSP00000428237 |
Frequencies
GnomAD3 genomes AF: 0.120 AC: 18284AN: 151894Hom.: 3114 Cov.: 32
GnomAD3 genomes
AF:
AC:
18284
AN:
151894
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0290 AC: 10563AN: 364450Hom.: 859 Cov.: 0 AF XY: 0.0279 AC XY: 5298AN XY: 190104
GnomAD4 exome
AF:
AC:
10563
AN:
364450
Hom.:
Cov.:
0
AF XY:
AC XY:
5298
AN XY:
190104
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.121 AC: 18349AN: 152012Hom.: 3135 Cov.: 32 AF XY: 0.117 AC XY: 8697AN XY: 74332
GnomAD4 genome
AF:
AC:
18349
AN:
152012
Hom.:
Cov.:
32
AF XY:
AC XY:
8697
AN XY:
74332
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
178
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:4Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 18, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 27, 2019 | This variant is associated with the following publications: (PMID: 25566792, 27055971, 9017514, 18922999) - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Hyperlipoproteinemia, type I Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Hyperlipidemia, familial combined, susceptibility to Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Feb 01, 2001 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at